Selective HDAC Inhibitors Targeting Class IIa Enzymes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions mediated by histone deacetylases (HDACs) lack effective inhibitors that can selectively target specific HDAC classes, such as Class IIa HDACs, which are involved in various diseases including neurodegenerative disorders, cancer, and psychiatric conditions, without causing unrelated biological effects at lower concentrations.
Innovation Solution
Development of a compound of Formula I or its pharmaceutically acceptable salts, which are selective inhibitors of HDACs, particularly targeting Class IIa HDACs, by structurally featuring specific substituents that allow for potent inhibition with minimal off-target effects, thereby providing a therapeutic option for conditions like Alzheimer's, Parkinson's, and depression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HDAC inhibitor treatments are used, then HDAC activity is inhibited, but off-target biological effects occur at lower concentrations
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific structural features (hydroxamic acid or carboxylic acid groups combined with particular aromatic or heteroaromatic moieties) that confer selective affinity for Class IIa HDACs. This localized structural optimization enables the inhibitor to distinguish between different HDAC classes, achieving high selectivity for HDAC4, HDAC5, and HDAC9 while avoiding off-target effects on other HDAC isoforms.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the inhibitor structure (substituents on aromatic rings, linker lengths, acid group types) to optimize binding affinity and selectivity. By adjusting these chemical parameters, the invention achieves potent inhibition of Class IIa HDACs at nanomolar concentrations while maintaining selectivity and avoiding the off-target effects that plague less optimized inhibitors.
2Reliability
If selective HDAC inhibitors are developed, then therapeutic efficacy is improved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a hydroxamic acid or carboxylic acid group for zinc coordination, an aromatic or heteroaromatic moiety for hydrophobic interactions and selectivity, and optional substituent groups for fine-tuning properties. This modular segmentation allows systematic optimization of each segment's contribution to binding affinity and selectivity while maintaining overall molecular manageability.
Solution Approach 2:
The patent employs composite materials by combining different chemical building blocks (aromatic rings, heteroaromatic systems, acid groups, and substituent moieties) into a composite molecular structure. This composite approach leverages the synergistic effects of different functional groups to achieve high selectivity and potency while providing a systematic framework for drug optimization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively inhibits HDAC activity at therapeutically relevant concentrations, offering a potential treatment for a wide range of diseases mediated by HDACs, including neurodegenerative disorders and cancer, with improved selectivity and reduced side effects.
Implementation Method 1
Histone deacetylases (HDACs) are zinc-containing enzymes which catalyse the removal of acetyl groups from the ε-amino termini of lysine residues
Implementation Method 2
HDACs are zinc-containing enzymes
Data Source
AI summary
Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.